Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study)

Of the 249 randomized participants, 246 (98.8%) completed the study.

• Mean percentage weight loss after 24 weeks was -14.39% in the test arm and -14.61% in the reference arm.
• The difference in weight loss between the test and reference arms was 0.15%, meeting the non-inferiority criterion.
• Weight loss greater than 10% was achieved by 86.67% in the test arm and 83.95% in the reference arm.
• Weight loss greater than 15% occurred in 38.79% of the test arm and 40.74% of the reference arm.
• Mean body mass index decreased by -4.93 kg/m² in the test arm and -5.00 kg/m² in the reference arm.
• Treatment-emergent adverse events were reported in 55.42% of test-arm participants and 54.22% of reference-arm participants.

AI simplified